Treatments for the Growing Problem of Hearing Loss – Sensorion’s Nawal Ouzren
Brainstorm Considering Right To Try For ALS Therapy
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury.
Companies to Watch: Sensorion
Sensorion is a public company in France developing new medicines for diseases of the inner ear, with two compounds in the pipeline: SENS- 111 for treating acute unilateral vestibulopathy…
Is Hearing Loss a Necessary Price for Children to Pay for Life-Saving Chemotherapies
We spoke to Nawal Ouzren, CEO of Sensorion, which will participate in the FDA meeting and is developing a treatment for sudden hearing loss that may be able to help pediatric cancer patients experiencing cisplatin-induced ototoxicity.
Cancer Treatment Developer Rain Therapeutics Closes $18.4 Million Series A
Rain Therapeutics Inc., a Fremont, Calif.-based developer of small molecule therapeutics for patients with cancer, has secured $18.4 million in Series A funding. Biotechnology Value Fund led the round, with participation from investors including Perceptive Advisors and Auckland UniServices Ltd.’s Inventors Fund.
The Case for a Daily Self-Injection to Treat Hemophilia
We spoke to Nassim Usman, CEO of Catalyst, about the company’s approach to hemophilia, how its drugs work, and why he believes his company’s pipeline may provide better alternatives for hemophilia patients.
